MDxHealth (NASDAQ:MDXH) & Aclarion (NASDAQ:ACON) Critical Survey

MDxHealth (NASDAQ:MDXH – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MDxHealth and Aclarion, as provided by MarketBeat.

MDxHealth presently has a consensus target price of $7.50, suggesting a potential upside of 275.00%. Aclarion has a consensus target price of $1.50, suggesting a potential upside of 756.65%. Given Aclarion’s higher possible upside, analysts plainly believe Aclarion is more favorable than MDxHealth.

Earnings and Valuation

This table compares MDxHealth and Aclarion”s gross revenue, earnings per share and valuation.

Aclarion has lower revenue, but higher earnings than MDxHealth.

Institutional and Insider Ownership

7.5% of Aclarion shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 22.3% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

MDxHealth has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares MDxHealth and Aclarion’s net margins, return on equity and return on assets.

Summary

Aclarion beats MDxHealth on 6 of the 11 factors compared between the two stocks.

About MDxHealth

(Get Free Report)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About Aclarion

(Get Free Report)

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.